优泌乐50与诺和灵50R治疗2型糖尿病的临床观察

目的比较优泌乐50和诺和灵50R治疗口服降糖药失败的2型糖尿病的临床疗效和安全性。方法选取2011年6月—2012年10月我院就诊的2型糖尿病患者60例，随机分为优泌乐50组和诺和灵50R组，每组30例。观察两组治疗12周后空腹血糖、餐后2h血糖、糖化血红蛋白（HbA）、低血糖及胰岛素用量等指标的差异。结果两组患者治疗后空腹血糖、餐后2h血糖、HbA均较治疗前下降，差异有统计学意义（P〈0．05）。治疗12周后，两组空腹血糖jHbA，。比较差异无统计学意义（P〉0．05），而优泌乐50组餐后2h血糖较诺和灵50R组降低，差异有统计学意义（P〈O．05）；治疗后两组日胰岛素用量相当，两组比较差异无统计学意义（P〉0．05）。在整个12周治疗观察期间，优泌乐50组记录到低血糖事件6次，诺和灵50R组记录到低血糖事件14次，两组均未发现严重低血糖事件。两组低血糖发生次数比较，差异有统计学意义（P〈0．05）。结论优泌乐50与诺和灵50R均能有效控制血糖，但优泌乐50在餐后血糖控制及减少低血糖方面优于诺和灵50R。

Study of Humalog Mix 50 and Novolin 50R in Treatment of Patients with Type 2 Diabetes Mellitus

Objective To evaluate the efficacy and safety of Humalog mix 50 and Novolin 50R in the treatment of type 2 diabetes mellitus and inadequate glycaemic control on oral therapy. Methods Sixty patients with type 2 diabetes mellitus and inadequate glycaemic control on oral therapy were divided randomly into humalog mix 50 group and Novolin 50R group. Af- ter a 12 -weeks observation period, the following indicators were observed and compared： fasting plasma glucose （FPG）, postprandial plasma glucose （2h -PPG）, glycosylated hemoglobin （HbAlo）, the incidence of hypoglycemia and total amount of insulin; Results Two groups of patients after treatment, FPG, 2h - PPG, HbAlo were decreased than those before treat- ment, the difference was statistically significant （P 〈0. 05）. After 12 weeks of treatment, the two groups had no statistically significant difference in HbAic, FPG （P 〉0. 05）, while the Humalog mix 50 group 2h PPG Novolin 50R group decreased, the difference was statistically significant （P 〈 0. 05） ; the two groups after treatment daily insulin dosage, the difference between the two groups was not statistically significant （P 〉 O. 05）. During the observation throughout the 12 weeks of treatment, huma- log mix 50 group of records to humalog hypoglycemic events 6, Novolin 50R group recorded hypoglycemic events 14 times, two groups were not found in severe hypoglycemia, compared the number of two groups othypoglycemia, the difference was statisti- cally significant （P 〈 O. 05）. Conclusion Humalag mix 50 and Novolin 50R are both effective in treatment of type 2 diabetes. Humalog mix 50/50 is superior to Novolin 50R in the control of postprandial plasma glucose and preventing hypoglycemia.